Abbott  Laboratories NYSE: ABT is a premier buy-and-hold stock because of its foresightful management, quality operation, portfolio, pipeline, cash flow, and capital return. It’s not always a good buy; all healthcare stocks have ups and downs in their cycles, but Abbott is a buy today, no matter how it moves. Abbott Laboratories TodayABTAbbott Laboratories$104.68 +1.96 (+1.91%) 52-Week Range$89.67▼$121.64Dividend Yield2.10%P/E Ratio32.61Price Target$120.18Add to WatchlistAbbott’s stock price trades in a ran ...

Exhibit 99.1 9.1 News Release Abbott Reports Second-Quarter 2024 Results and Raises Full-Year Guidance – Sales of $10.4 billion driven by strong underlying base business performance – Reported sales growth of 4.0 percent; organic sales growth for underlying base business of 9.3 percent , led by double-digit growth in Medical Devices – Continues to strengthen portfolio with new product approvals 1 ABBOTT PARK, Ill., July 18, 2024 — Abbott today announced financial results for the second quarter ended June 30 ...

Sales of $10.4 billion driven by strong underlying base business performance Reported sales growth of 4.0 percent; organic sales growth for underlying base business of 9.3 percent1, led by double-digit growth in Medical Devices Continues to strengthen portfolio with new product approvals ABBOTT PARK, Ill., July 18, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2024. Second-quarter GAAP diluted EPS of $0.74 and adjusted diluted EPS of $1.1 ...

These stocks don't appeal only to dividend seekers.Stocks that can survive and thrive for long periods -- say, beyond 20 years -- are a special breed. These companies typically display one or several of the following characteristics: innovative abilities, leadership in a major industry, a strong moat, or exciting growth potential. That's not an exhaustive list of traits such corporations can have, but they are among the most important.To find businesses that display them, it can be helpful to start by looki ...

Loading...Loading...Abbott Laboratories ABT is scheduled to release its financial results for the second quarter, before the opening bell on Thursday, July 18.Analysts expect the North Chicago, Illinois-based company to report quarterly earnings at $1.10 per share, up from $1.08 per share in the year-ago period. Abbott expects to post revenue of $10.37 billion. It posted $9.7 billion a year earlier, according to data from Benzinga Pro.On June 14, Abbott declared a quarterly common dividend of 55 cents per s ...

Core Insights - Abbott is expected to report Q2 2024 results on July 18, with projected revenue of $10.3 billion and earnings of $1.10 per share, aligning with market expectations [1] - The stock has underperformed compared to the S&P 500 over the past three years, with returns of 29% in 2021, -22% in 2022, and 0% in 2023, while the S&P 500 saw returns of 27%, -19%, and 24% respectively [1] - Abbott's stock is currently valued at $103, with an estimated valuation of $123 per share, indicating a potential growth of about 20% [3] Financial Performance - In Q1 2024, Abbott reported revenue of $10 billion, a 2.2% year-over-year increase, with a 14% rise in medical device sales and a 5% increase in nutrition sales [4] - The diagnostics segment saw an 18% decline in revenue due to reduced demand for COVID-19 testing, although excluding COVID-19 tests, diagnostics sales increased by 2.7% [4] - The adjusted pre-tax income margin decreased by 120 basis points year-over-year to 20.4%, resulting in a 5% decline in adjusted earnings to $0.98 [4] Segment Growth Expectations - For Q2 2024, Abbott is expected to see growth across its segments, particularly in nutrition due to market share gains in baby formula products and increased sales in medical devices driven by higher procedure volumes [5] - The FreeStyle Libre product is anticipated to continue driving growth in diabetes sales, while COVID-19 testing sales are expected to decline from $263 million in Q2 2023, slightly offsetting growth in core laboratory diagnostics [5]

Over the years, especially the past three, I have become more cautious about the technology sector’s blatant overvaluation. Nevertheless, it is difficult to ignore the capabilities of companies such as Nvidia (NASDAQ:NVDA) and their innovative solutions for AI. Although, in my opinion, the market’s optimism has still led to high valuations. This is why I am shifting my focus to undervalued healthcare stocks as a means of protecting myself from the overvaluation of the technology sector.I think that the heal ...

Abbott Laboratories (ABT) is slated to report its second-quarter 2024 results on Jul 18, before the opening bell.The company posted adjusted earnings per share (EPS) of 98 cents in the last quarter, which topped the Zacks Consensus Estimate by 2.08%. In the trailing four quarters, its earnings exceeded the Zacks Consensus Estimate on all four occasions, the average beat being 2.39%.Q2 EstimatesThe Zacks Consensus Estimate for ABT’s second-quarter 2024 revenues is pegged at $10.35 billion. This suggests a 3. ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Abbott (ABT) .Abbott currently has an average brokerage recommendation (AB ...

In my view, it’s important for every individual to invest in equities. By just holding cash in a back account, there is bound to be loss of purchasing power when adjusted for inflation. To maintain or increase purchasing power, investors need exposure to risky asset classes.However, not all investors have the appetite for high-risk that’s associated with growth or penny stocks. The remedy is to invest in low-beta stocks that deliver steady returns and protect the portfolio from extreme volatility. The focus ...